19 April 2016 - Deborah Wilkes
Archived
Advisers to the US Food and Drug Administration (FDA) have voted in favour of Galderma's application to switch adapalene – the active ingredient of its acne medicine Differin – from prescription to OTC status.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.